Navigation Links
Study Suggests Osteoporosis Drug Might Treat Loss of Bone in Jaw
Date:10/18/2010

By Amanda Gardner
HealthDay Reporter

SATURDAY, Oct. 15 (HealthDay News) -- People suffering from a disfiguring loss of bone in the jaw may find help in the form of a long-used osteoporosis drug, two new studies suggest.

Besides being linked to chronic, severe gum disease, this type of bone loss has also been connected in rare cases to the use of bisphosphonates, a different class of osteoporosis drugs.

But the two papers in the Oct. 16 online issue of the New England Journal of Medicine report success with teriparatide (Forteo) in rebuilding bone.

One report describes the case of an 88-year-old woman who had been taking the bisphosphonate alendronate (Fosamax) since suffering a hip fracture 10 years earlier. She had also been taking the corticosteroid prednisone for two decades.

Experts have already noticed an uptick in the incidence of this rare but devastating condition in patients using bisphosphonates.

According to an editorial accompanying the study, this complication occurs in about 5 percent of cancer patients who are taking a high-dose bisphosphonate (Zometa or Aredia) to control or prevent spread of malignancy to the bone. It is much rarer in people who take a lower-dose bisphosphonate (such as Actonel, Boniva or Fosamax) for osteoporosis.

The 88-year-old woman described in the journal report had been experiencing pain in her jaw for a year and was subsequently diagnosed with osteonecrosis, a debilitating "death" of bone due to loss of blood flow.

After eight weeks of treatment with Forteo, though, the pain went away and the osteonecrosis resolved, reported the authors, from Austin Health in Melbourne, Australia.

The editorial pointed out, however, that Forteo should not be used in patients whose cancer has already spread to the bone, as it might prompt even more spread.

It's also possible that the corticosteroid therapy she was taking could have contributed to the woman's bone loss, the authors stated.

The second paper involved 40 patients with severe gum disease that had affected their jaws, all of whom first underwent surgery on their jaw. They were then randomized to receive either Forteo or a placebo. All participants took calcium and vitamin D as well.

"These were patients with severe periodontal disease but who were otherwise systemically healthy," said study senior author Dr. Laurie K. McCauley, chair of the department of periodontic and oral medicine at the University of Michigan in Ann Arbor.

After six weeks of therapy, patients in the Forteo arm saw greater healing of their jawbone and this continued throughout one year of follow-up.

"There was a significant improvement in clinical measures of gum and bone," McCauley stated.

But, she pointed out, Forteo is not yet approved for this indication, so "we can't recommend it next week."

Right now, a bone graft is probably the most common type of therapy for this type of bone loss, she said.

"I think that it's really an important important proof-of-concept that you can inject locally and get a response," said Dr. Rena D'Souza, chair of biomedical sciences at Texas A&M Health Science Center Baylor College of Dentistry in Dallas. "We could not only use this approach for the treatment of periodontal disease where the disease enters the bone and gum. but also other forms of periodontal disease."

"Bisphosphonates cut back on blood flow and blood vessels so that cancer doesn't have a chance," she said. "That is why it's used very effectively for cancer but if you happen to injure the bone or take out a tooth you really need the blood vessels. The bone cells don't have the ability to lay down new bone."

More information

The American Academy of Periodontology has more on gum disease.

SOURCES: Laurie K. McCauley, D.D.S., Ph.D., professor and chair, department of periodontic and oral medicine, University of Michigan, Ann Arbor; Rena D'Souza, chair, biomedical sciences, Texas A&M Health Science Center Baylor College of Dentistry, Dallas; Oct. 16, 2010, New England Journal of Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Suggests Osteoporosis Drug Might Treat Loss of Bone in Jaw
(Date:1/23/2017)... ... January 23, 2017 , ... ... with the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education ... of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... education programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching ... diet. These resources have been developed for use by nutrition educators and ...
(Date:1/22/2017)... ... 22, 2017 , ... Phytocéane invites clients to take an exotic journey deep ... with ZANZIBAR MILKY CREAM. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off ... moisturizing vegetal coral to create this gentle, velvety body cream to envelop the skin ...
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian company ... ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding meetings with ... of its beauty and wellness products. At this trade show, the company had the ...
(Date:1/21/2017)... ... , ... Phytocéane invites you to take an exotic journey deep ... with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off ... vegetal coral to create this gentle, crystal-clear shower gel to cleanse the body and ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Varias proteínas clave que ... y el riesgo de diálisis están poco ...    Resverlogix Corp. ("Resverlogix" o "la compañía") ... ensayo en fase 1 con sede en Nueva Zelanda ... Los datos demostraron unos resultados importantes en la reducción ...
(Date:1/23/2017)... , January 23, 2017 The global  anxiety disorders ... billion by 2025. The rising incidence of depression worldwide is anticipated to drive ... has resulted in the declining demand for antidepressants in the recent years. ... ... Grand View Research Logo ...
(Date:1/23/2017)... 23, 2017 InDex Pharmaceuticals Holding AB (publ) ... 12th congress of the European Crohn,s and Colitis Organisation (ECCO). The ... specific focus on inflammatory bowel disease (IBD). The congress is held ... ... pleased to again having been selected to present data at the ...
Breaking Medicine Technology: